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Objective: Preterm brain injury is a major cause of disability in later life, and may result in motor, cogni-
tive and behavioural impairment for which no treatment is currently available. The aetiology is consid-
ered as multifactorial, and one underlying key player is inflammation leading to white and grey matter
injury. Extracellular vesicles secreted by mesenchymal stem/stromal cells (MSC-EVs) have shown thera-
peutic potential in regenerative medicine. Here, we investigated the effects of MSC-EV treatment on brain
microstructure and maturation, inflammatory processes and long-time outcome in a rodent model of
inflammation-induced brain injury.
Methods: 3-Day-old Wistar rats (P3) were intraperitoneally injected with 0.25 mg/kg lipopolysaccharide
or saline and treated with two repetitive doses of 1  108 cell equivalents of MSC-EVs per kg bodyweight.
Cellular degeneration and reactive gliosis at P5 and myelination at P11 were evaluated by immunohisto-
chemistry and western blot. Long-term cognitive and motor function was assessed by behavioural test-
ing. Diffusion tensor imaging at P125 evaluated long-term microstructural white matter alterations.
Results: MSC-EV treatment significantly ameliorated inflammation-induced neuronal cellular degenera-
tion reduced microgliosis and prevented reactive astrogliosis. Short-term myelination deficits and long-
term microstructural abnormalities of the white matter were restored by MSC-EV administration.
Morphological effects of MSC-EV treatment resulted in improved long-lasting cognitive functions
Interpretation: MSC-EVs ameliorate inflammation-induced cellular damage in a rat model of preterm
brain injury. MSC-EVs may serve as a novel therapeutic option by prevention of neuronal cell death,
restoration of white matter microstructure, reduction of gliosis and long-term functional improvement.
 2016 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
The rate of prematurely born infants has increased up to
amounts of 10–12% of all live births attributable to late mother-hood and infertility treatments (Beck et al., 2010; Mathews et al.,
2011). Major progress in obstetric and neonatal care has signifi-
cantly reduced mortality but more than 50% of survivors still
remain at risk to suffer from long-term neurological sequelae.
Beside severe motor impairment, cognitive disorders and neu-
ropsychiatric problems including autism, attention deficit and
hyperactivity disorders are often observed in long-term follow-
up studies (Belmonte et al., 2004; Johnson et al., 2011; Wilson-
Costello et al., 2005). Since the rate of severe cerebral palsy as a
result from cystic periventricular leukomalacia has declined in
recent years, diffuse cerebral white matter injury (WMI) is now
the major type of brain damage (Benders et al., 2014). These subtle
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ciated with altered development of the myelin sheath and consec-
utively altered cortical development leading to cognitive and
behavioural deficits (Donega et al., 2014; Favrais et al., 2011).
According to the ‘‘multiple hit hypothesis”, a variety of noxious
events such as fluctuations in oxygen supply caused by acute or
chronic lung disease, drug exposure and inflammation may affect
the developing brain and thereby result in cellular loss and matu-
ration disturbances (Anjari et al., 2009; Brehmer et al., 2012; Cai
et al., 2000; Felderhoff-Mueser et al., 2004; Kaindl et al., 2009). Pre-
disposing factors for WMI are intrauterine and perinatal infections
leading to systemic inflammation (Andrews et al., 1995; Hagberg
and Mallard, 2005; Randis, 2010).
In preclinical studies, lipopolysaccharide (LPS) is used in exper-
imental models to mimic the clinical situation (Brehmer et al.,
2012; Eklind et al., 2001). In the clinical setting injurious stimuli
may cause injury at different time points, making it difficult to
identify the underlying insult. Therefore, neuroprotective treat-
ments with preventive and/or regenerative properties are urgently
needed. However, to date clinically applicable therapeutic options
in preterm infants remain elusive.
Mesenchymal stem/stromal cells (MSCs) have been widely
used in experimental and clinical paradigms such as stroke
(Hess and Hill, 2011; Mendez-Otero et al., 2007), multiple
sclerosis (Gerdoni et al., 2007; Orack et al., 2015), cardiovascular
diseases (Williams and Hare, 2011), and graft-versus-host disease
(Baron and Storb, 2011; Le Blanc et al., 2004). Preclinical studies
using models of birth asphyxia and preterm white matter injury
confirmed the neuroprotective capacities of MSCs after local,
systemic or even intranasal application (Ohshima et al., 2015;
van Velthoven et al., 2013; Wei et al., 2015). Beneficial effects
were observed, independently of whether autologous or
allogenic MSCs were administered. According to their multiple
differentiation capabilities MSCs were initially thought to home
to affected tissues, replace lost or damaged cell types and
modulate immune responses (Bianco et al., 2013; Wang et al.,
2014). In recent years, however, increasing evidence suggests that
their therapeutic effects are rather mediated in a paracrine
manner (Gnecchi et al., 2005; Hsieh et al., 2013; Lee et al.,
2009) mainly being mediated by extracellular vesicles (EVs), such
as exosomes and microvesicles (Börger et al., 2016; Bruno et al.,
2009; Doeppner et al., 2015; Kordelas et al., 2014; Lai et al.,
2010; Lener et al., 2015).
EVs are naturally occurring membrane-surrounded vesicles and
released by almost all cell types into the extracellular environment.
Exosomes, derivatives of the late endosomal compartment (70–
150 nm), and microvesicles, bud offs of the plasma membrane
(100–1000 nm), are the most prominent EV types. Both are assem-
bled in cell type specific manners containing specific cargo combi-
nations of lipids, RNA, cell-adhesion-molecules, cytokines, and
other proteins. They mediate intercellular communication pro-
cesses and transmit tailored information to specific target cells
(Ludwig and Giebel, 2012; Yanez-Mo et al., 2015). According to
their unique features, EVs provide promising tools in immune
and regenerative therapies and may also be used for targeted drug
delivery (Lener et al., 2015). In contrast to cells, they lack any
endogenous tumour-formation potential and are easier to handle.
Furthermore, due to their small size they can be sterilized by filtra-
tion (Lener et al., 2015).
Here, we hypothesised that MSC-EV treatment yields
therapeutic potential for preterm white matter injury. Using an
established rodent model of perinatal inflammation, early effects
on cellular degeneration, reactive gliosis, and myelination
were analysed. Long-term structural alterations of the white
matter were characterized by diffusion tensor imaging and
behavioural testing.2. Material and methods
2.1. Expansion and characterization of MSCs
MSCs were raised from bone marrow (BM) samples of anon-
ymised human donors following informed consent according to
the Declaration of Helsinki as previously described. Briefly BM-
derived mononuclear cells were harvested by Ficoll (Biocoll
Separating Solution; Biochrom AG Berlin Germany) density gradi-
ent centrifugation and seeded at a density of 2  106 cells per well
into 6-well tissue culture plates containing MSC basal media (Pan-
Biotech Aidenbach Germany) supplemented with 10% human
thrombocyte lysate 1% glutamine and 1% penicillin-streptomycin
(Invitrogen Darmstadt Germany). After 24 h non-adherent cells
were removed by medium exchange. After reaching confluence
cells were continuously passaged. MSCs were characterized by
flow cytometry and tested for their differentiation potential
(Doeppner et al., 2015; Kordelas et al., 2014).2.2. Enrichment of EVs from conditioned MSC media
After passage 3, MSC conditioned media (CM) were harvested
every 48 h, passed through a 0.22 lm filter membrane (TPP
TechnoPlastic Products AG, Trasadingen, Switzerland) to remove
cell debris and larger vesicles and stored at 20 C. After thawing,
CMs were centrifuged at 10,000g in an Avanti J-26 XP centrifuge
(Beckmann Coulter, Germany) for 30 min. Subsequently, EVs
within supernatants were concentrated by a polyethyleneglycol
(PEG) precipitation method (Kordelas et al., 2014). Briefly,
PEG6000 (50% wt/vol; Sigma-Aldrich, Taufkirchen, Germany) and
NaCl were added to a final concentration of 10% PEG and 75 mM
NaCl and incubated for 8–12 h at 4 C. EVs were concentrated by
centrifugation for 30 min at 1500g. To reduce the amount of co-
precipitated proteins pellets were resolved in normal saline (B.
Braun Melsungen, Melsungen, Germany) to a total volume of
45 ml; EVs were re-precipitated by ultracentrifugation for 2 h at
110,000g in an Optima L7-65 ultracentrifuge using the tight angle
rotor Ti45 (Beckman Coulter). EV pellets were diluted in saline to a
concentration of 4  107 cell equivalents/1 ml. Aliquots were
stored at 80 C until usage. EV samples were characterized by
Nanoparticle Tracking Analyses (NTA) (Sokolova et al., 2011) on
the ZetaView platform (Particle Metrix, Meerbuch, Germany). The
presence of exosomal marker proteins (Tsg101 or CD81) was con-
firmed by western blot. Samples were tested for contamination
with HIV-1, HIV-2, HCV and HBV by multiplex PCR using the Pro-
cleix Ultrio Elite kit (Grifols Deutschland GmbH, Frankfurt am
Main, Germany). To test for microbiological contamination 100 ll
of each EV sample were diluted with saline to a total volume of
1 ml. Subsequently the diluted EV solution was inoculated into
BactTAlert bottles (bioMerieux, Nürtingen, Germany). Bottles were
incubated at 32 ± 1 C for 14 days, and automatic readings were
taken every 10 min. All samples used were negative in all assays.2.3. Experimental animals
All animal procedures were performed in accordance with the
international guidelines for good laboratory practice and the insti-
tutional guidelines of the University Hospital Essen approved by
the animal welfare committees of North Rhine Westphalia. Pups
were kept under a 12 h light/dark cycle and had free access to food
and water after separation form their dams. All groups were sex-
and weight matched.
3-Day-old (P3) Wistar rat pups were randomly assigned to
treatments. Pups were equally distributed to control for maternal
care. Four experimental groups were treated with intraperitoneal
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(saline NaCl 0.9%); (2) vehicle and MSC-EVs (1  108 cell equiva-
lents/kg bodyweight) at 3 h before and 24 h after vehicle injection;
(3) LPS 0.25 mg/kg (E. coli O55:B5, Sigma-Aldrich, Steinheim, Ger-
many; in saline with a volume of 0.01 ml/g); (4) LPS and MSC-
EVs at 3 h before and 24 h after a single LPS injection.
In total, 173 pups (saline (1): n = 45, MSC-EV (2): n = 38, LPS (3):
n = 46, LPS/MSC-EV (4): n = 44) derived from 14 litters were
enrolled. Rats were sacrificed at P5, P11 and P125. In the first set
of experiments 85 rats were used to assess apoptosis, micro- and
astrogliosis via western blot and immunohistochemistry on P5
(saline (1): n = 21, MSC-EV (2): n = 20, LPS (3): n = 22, LPS/MSC-
EV (4): n = 22). These animals were also used for quantification
of pro-inflammatory plasma and cerebral cytokine levels. A second
cohort was used for western blot analysis and qualitative evalua-
tion of myelin basic protein (MBP) expression on P11 (saline (1):
n = 15, MSC-EV (2): n = 10, LPS (3): n = 14, LPS/MSC-EV (4):
n = 12). In accordance with previous studies of our group cellular
degeneration was determined at P5 and myelination at P11
(Brehmer et al., 2012; Felderhoff-Mueser et al., 2004).
A third set of experimental animals was used for behavioural
testing (saline (1): n = 9, MSC-EV (2): n = 8, LPS (3): n = 10, LPS/
MSC-EV (4): n = 10). Out of these, brains of 6 animals of each
experimental group were subjected to diffusion tensor imaging
on P125. Animals subjected to behavioural testing and DTI were
weaned at P21 and housed in groups of 4–5 animals per cage.
Bodyweight as a sign for general health was recorded at P3, P4,
P5, P11 and once a week after the weaning period for behavioural
studies. Neurodevelopmental outcome was assessed from P30 and
P90. Post-mortem Diffusion Tensor-Magnetic Resonance Imaging
(DT-MRI) was carried out at P125 to evaluate long-term
microstructural white matter changes. For western blot analysis,
pups were transcardially perfused with phosphate buffered saline
(PBS), the olfactory bulb and the cerebellum were removed, and
brain hemispheres and white matter enriched fractions (including
corpus callosum, deep cortical white matter and external capsule)
were snap-frozen in liquid nitrogen and stored at 80 C until fur-
ther analysis. Whole hemispheres were used for western blot for
overall evaluation of myelination. To correlate specific effects on
myelination with local inflammatory reactions white matter
enriched fractions were used as previously described (Serdar
et al., 2016). For histological analysis pups were transcardially per-
fused with PBS followed by 4% paraformaldehyde (PFA, Sigma-
Aldrich). Brains were removed and post-fixed in 4% PFA overnight
at 4 C and embedded in paraffin. MRI brains were post-fixed in 4%
PFA for four days and stored in 1% PFA until further analysis.
2.4. Immunoblotting
Snap-frozen hemispheres (for analysis of MBP) or white matter
enriched fractions were homogenized in ice-cooled radioimmuno-
precipitation assay (RIPA) buffer, supplemented with phenyl-
methanesulfonyl fluoride (PMFS, Sigma-Aldrich) and complete
Mini, EDTA-free (Roche, Basel, Switzerland). Homogenates were
centrifuged at 3000g for 10 min followed by 17,000g for 20 min.
Protein concentrations in the remaining cytosolic extracts were
determined using the BCA assay kit (Thermo Fisher Scientific,
Dreieich, Germany). Lysates were denatured in Laemmli sample
buffer at 95 C for 10 min and separated by 15% or 8% sodium
dodecyl sulfate polyacrylamide gel electrophoresis, followed by
blotting onto nitrocellulose membranes (0.2 lm or 0.4 lm pore,
Protran, Sigma-Aldrich). Equal loading and transfer of proteins
was confirmed by staining of membranes with Ponceau S solution
(Sigma-Aldrich). 5% non-fat dry milk in Tris buffered saline/0.1%
Tween 20 (TBST) was used for blocking nonspecific protein binding
at room temperature for 60 min. Membranes were incubated over-night (4 C) with the primary antibody in 5% non-fat dry milk in
TBST. The following primary antibodies were used: rabbit-anti-
cleaved Caspase 3 (cCaspase 3 1:1000, Cell Signaling Technology,
Boston, USA), rabbit-anti-Iba1 (1:1000, Wako Pure Chemical Indus-
tries, Osaka, Japan), mouse-anti-MBP antibody (1:10,000, Abcam,
Cambridge, UK) and mouse-anti-glial fibrillary acidic protein
(GFAP) (1:500, Covance, Münster, Germany). Horseradish
peroxidase-conjugated secondary antibodies directed against the
specific host species were used for detection. Signals were visual-
ized using enhanced chemiluminescence (ECL; GE Healthcare Eur-
ope GmbH, Freiburg, Germany) and quantified using the ChemiDoc
XRS+ imaging system and Image Lab software (Bio-Rad, Munich,
Germany).
2.5. Immunohistochemistry
Terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end labelling (TUNEL) assays were performed on 10 lm
coronal paraffin sections according to the manufacturer0s instruc-
tions (In Situ cell death detection kit, FITC; Roche) at P5. After
deparaffinisation, coronal sections (3.72 ± 0.5 mm) were rehy-
drated. Antigen-retrieval was carried out in a pre-heated 10 mM
sodium-citrate buffer (pH 6,0) for 30 min. Sections were blocked
with 1% bovine serum albumin (Fraction V), 0.3% cold fish skin
gelatine and 0.1% Tween 20 (all Sigma-Aldrich) in Tris-buffered-
saline. For analysis of myelination, microglia and astrocytes sec-
tions were incubated with primary antibodies (mouse anti-MBP
(1:100, SMI-99, BioLegend, Sternberger Monoclonals, San Diego,
USA), mouse anti-CD68 (1:100, AbD Serotec, Puchheim, Germany),
rabbit anti-Iba-1 (1:500, Wako), mouse anti-GFAP (1:100, Conva-
nce)) overnight at 4 C, followed by secondary antibody incubation
(anti-mouse Alexa Fluor 488, anti-rabbit Alexa Fluor 488, anti-
mouse Alexa Fluor 555, 1:500 Invitrogen, Darmstadt, Germany)
for 1 h at room temperature. For nuclear staining sections were
incubated for 10 min with 40,6-Diamidin-2-phenylindol (DAPI,
100 ng/mL; Invitrogen). Slides were mounted with Fluorescent
Mounting Medium and kept in the dark at 4 C.
2.6. Analysis of pro-inflammatory cytokines
For analysis of cytokines in serum, blood was collected from the
right atrium before perfusion. Serum was prepared after clotting in
uncoated tubes by centrifugation at 3000g for 5 min. Cytokines
were determined using Bio-Plex ProTM Rat Cytokine Assay (Bio-
Rad). Data were acquired with Luminex 200 and IS2.3/xPONENT3.1
software and further processed with the R package nCal. Standard
curves were fitted by logistic regression to estimate absolute con-
centration of analytes.
Cerebral cytokines were measured using real time PCR. Total
RNA was isolated from snap-frozen tissue by acidic phenol/chloro-
form extraction (peqGOLD RNAPureTM; PEQLAB Biotechnologie,
Erlangen, Germany) and 4lg of RNA were reverse transcribed.
Gene expression analysis was performed as previously described
using the StepOne plus (Applied Biosystems, Foster City, CA, USA
(Brehmer et al., 2012)). The PCR products of interleukin 1b (IL-
1b), tumor necrose factor a (TNF-a), interleukin 18 (IL-18) and b-
actin (as internal standard) were quantified in real time, by fluoro-
genic reporter oligonucleotide probes and primers (Biotez, Berlin,
Germany). Sequences and corresponding GenBank accession num-
bers are provided in Supplemental Table 1. Real-time PCR and
detection were performed in duplicates, measurements repeated
2 times for each sample. Target gene expression was quantified
according to the 2DDCT method.
IL-1b protein expression was analysed in brain lysates using an
IL-1b ELISA kit (R&D Systems, Wiesbaden, Germany) according to
the manufacturer’s instructions.
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Brain sections were analysed by confocal microscopy (A1plus,
Eclipse Ti, with NIS Elements AR software, Nikon, Düsseldorf, Ger-
many). Optical sections were acquired with a field depth of 10 lm
(1 lm steps), using a 20x objective (Nikon N, Plan Apo VC
20x/0.75) and the NIS Elements AR Software. Two different filters
(DAPI (450/50-405 LP), Alexa Fluor 488 (515/20-540 LP) were used
for image acquisition. For analysis of TUNEL-stained sections,
images of two regions of interest (ROI, each: 396,900 lm2), in
white matter and cortex were acquired. TUNEL-positive cells were
counted by a blinded observer in two sections per animal and ROI.
For MBP staining complete hemispheres were scanned with a 10x
objective (Nikon N, Plan Apo, 10x/0.45). For analysis of astro- and
microgliosis, two ROIs in the cingulate white matter and the inter-
nal capsule were chosen as predominantly susceptible to LPS-
induced micro- and astrogliosis. The total number of CD68 and
Iba-1 positive cells was counted in these ROIs (total area:
585,900 lm2) and the number of cells/mm2 was calculated. Since
GFAP staining revealed densely packed networks of positive fibres
in LPS-treated animals not allowing counting of single cells, the
positively stained area was analysed as previously described
(Schafer et al., 2012; Sullivan et al., 2010) using the binary tool
of NIS AIR software (Nikon, Germany).
2.8. Behavioural studies
Animals were transferred to the behavioural unit one week in
advance of testing in order to familiarise them with the investiga-
tor and an inversed 12 h light/dark cycle. Behavioural testing with
all tests applied was performed in every animal starting at P30 in
adolescent and repeated from P90 in adult animals. We mainly
focused on assessment of cognitive function because clinical data
provide convincing evidence that long-term cognitive function is
impaired in a significant number of preterm infants (Marlow
et al., 2015). Based on these clinical indications combined with
recent experimental studies reporting a cognitive deficit after an
inflammatory stimulus (Favrais et al., 2011) we performed two dif-
ferent cognitive tests (Barnes Maze and Novel Object Recognition).
To rule out potential confounding effects by motoric impairment
or anxiety-related behaviour the Open Field test was applied.
One day of Open Field was followed by Novel Object Recognition
for 4 days and Barnes Maze for 4 days. Experiments were carried
out during the active phase. Data were recorded by using an auto-
matic tracking system (Video-Mot2, TSE Systems, Bad Homburg,
Germany) and exported for statistical analysis. The Open Field
was used to assess spontaneous motor-activity and anxiety-
related behaviour (DeFries et al., 1966; Karen et al., 2013). Animals
were placed in the centre of an Open Field arena (50  50  40 cm),
upon an infrared (IR) light-box (TSE Systems) emitting IR light
(850 nm) for 5 min. Activity parameters such as total distance
and velocity were analysed. Non-spatial, non-aversive memory
functions were assessed with Novel Object Recognition which relies
on the observation, that animals preferentially explore novel
objects over those that are familiar (Chambon et al., 2011). For
the Novel Object Recognition test, the time of direct head contacts
with the objects was recorded by the automated tracking system
Video-Mot2 (TSE Systems).
At the start of the experiment animals were placed in the centre
of the Y-maze and movements were recorded by a tracking system.
On the first day animals were habituated to the Y-maze without
objects followed by 2 training days with identical objects in each
arm of the maze. At day 4 a novel object was changed in one
arm and the time spent with familiar and novel objects were
recorded. Testing time per session was 5 min and the first minute
was used for quantification (Chambon et al., 2011). For Barnes Mazeanimals were placed in the centre of the maze (1.22 mwidth, 0.8 m
height, 20 holes at the border, TSE Systems) in a glass cylinder
under red light. Light was switched to bright light to provide
extra-maze cues as aid to orientation. After removing the cylinder
(30 s under bright light) the animal was allowed to explore the
maze and find the escape box within 120 s, where they were left
for 1 min. Animals who did not find the escape box were gently
placed into it for 1 min. To avoid intra-maze cues, such as material
surface or odour, the escape box was clockwise rotated for every
other animal, with the same escape location for each animal at
the three training days. We applied a training period for 3 days,
only, since our previous analyses revealed that all experimental
groups reached a similar level of latency to find the trained escape
box after three days in another model of preterm brain injury
(Serdar et al., 2016). To test adaptive memory function the spatial
probe test was applied on the fourth day by closing all holes i.e.
animals had to adapt to an altered environment which may lead
to increased latencies to find the trained escape hole (O’Leary
et al., 2011).2.9. Diffusion tensor-magnetic resonance imaging (DT-MRI)
Postmortem DT-MRI acquisition was performed in fixed brains
from animals sacrificed at P125. All experiments were performed
on an actively shielded horizontal 9.4T/31 cm magnet (Varian/
Magnex) equipped with 12 cm gradient coils (400 mT/m, 120 ls)
with a transceiver 25 mm birdcage volume RF coil. A spin echo
sequence with addition of the Stejskal-Tanner diffusion gradients
was used. Diffusion gradients were applied along six spatial direc-
tions: dual gradient diffusion gradient sampling scheme. Intensity,
duration and diffusion time were set to 22 G/cm, 3 ms and 20 ms
respectively, given a b-value of 1185 s/mm2. A field of view of
16  16 mm2 was sampled on a 128  64 cartesian grid. Multi-
slice DT images were acquired (12 slices of 0.5 mm thickness) in
the axial lane with 10 averages and TE/TR = 30/2000 ms. Using an
in house Matlab script (Mathworks, Natick, MA, USA), the radial
diffusivity (D\), the axial diffusivity (D//), the mean diffusivity
(MD) as well as fractional anisotropy were derived from the tensor.
The program allows manual delineation of the ROI on the fractional
anisotropy maps. For quantification the corpus callosum was
analysed.2.10. Statistical analysis
Prism 6 (GraphPad Software, San Diego, USA) was used for data
presentation and statistical analysis. Differences between groups
were determined by two-way analysis of variance (two-way
ANOVA) or three-way ANOVA (for learning behaviour) followed
by Tukey’s post hoc test for multiple comparisons. For MRI results,
nonparametric Mann–Whitney test was used. P-values less than
0.05 were considered as statistically significant.3. Results
To study the potential therapeutic impact of MSC-EVs in LPS
induced perinatal brain injury rats were treated with systemic
injections of either LPS or MSC-EVs or an application of both treat-
ments. There were no significant differences in weight gain
between experimental groups (data not shown). Out of 90 LPS-
treated animals (LPS and LPS/MSC-EV) one died in the LPS vehicle
group. No obvious side effects were detected. Furthermore, there
were no significant gender differences in our experiments.
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in the immature brain
Systemic application of LPS causes cellular degeneration and
apoptosis in the developing rat brain (Brehmer et al., 2012;
Lodygensky et al., 2014). To analyse the effect of MSC-EV treatment
inflammation-induced brain injury, cellular degeneration was
measured via western blot of cCaspase 3 protein expression in tis-
sue preparations of cortex and white matter at 48 h after LPS appli-
cation (i.e. 24 h after the second MSC-EV injection, P5). LPS
treatment led to a marked increase in cCaspase 3 expression,
which was significantly reduced by MSC-EV treatment (Fig. 1A).
To verify these results, immunohistochemistry was used to exam-
ine cell death in cortex and white matter revealing a significant
LPS-induced increase of TUNEL-positive cells in both brain regions.
This LPS-induced increase of TUNEL-positive cells was significantly
reduced upon treatment with MSC-EVs, in both, cortex and white
matter (Fig. 1B and C).3.2. MSC-EVs prevent reactive gliosis after inflammation-induced
perinatal brain injury
Since systemic LPS administration at P3 has been described to
trigger microglia activation and a strong induction of astrogliosis
(Lodygensky et al., 2014) the immunomodulatory effect of MSC-
EVs alone and after application of LPS was analysed 48 h after
LPS injection (i.e. 24 h after the last EV administration). Microglio-
sis was determined by western blot and immunohistochemistry of
Iba-1 and CD68, respectively. Compared to the saline treated con-
trol group, LPS treatment resulted in a significant increase of Iba-1
and CD68 positive cells and Iba-1 protein expression in white
matter-enriched brain fractions (Fig. 2A, B, D Supplemental
Fig. S1A). Co-treatment with MSC-EVs significantly reduced micro-
glia cell numbers and Iba-1 protein expression (Fig. 2A, B and D).
There was a marked but non-significant decrease in the number
of CD68 positive cells upon MSV-EV treatment in LPS exposed ani-
mals. Circularity was significantly reduced by a combination of
both LPS and MSC-EV treatment (Supplemental Fig. S1 A and B).
Reactive astrogliosis was determined by immunohistochemistry
and western blot analysis of GFAP. A densely packed network of
GFAP positive fibres and hypertrophic somata was observed in
LPS treated animals (Fig. 2A). Quantification of GFAP positive area
revealed a significant LPS response, which was ameliorated upon
MSC-EV co-treatment (Fig. 2C). These results were confirmed by
western blot analysis (Fig. 2E). Overall statistical analysis (two-
way ANOVA) of micro- and astrogliosis (Fig. 2) demonstrated sig-
nificant interaction effects between EVs and LPS (Iba-1: F (1,24)
= 46.75, p < 0.001; GFAP: F (1,24) = 4.85, p < 0.05), indicating that
EVs are particularly active in the case of LPS-induced inflammation.4. Modulation of pro-inflammatory cytokines by LPS and MSC-
EV treatment
Systemic and cerebral pro-inflammatory cytokine responses
were measured in serum and brain 24 h after the last MSC-EV-
injection (Fig. 3, Supplemental Fig. C and D). This specific time
point was chosen to correlate findings with our read-outs on cere-
bral apoptosis, micro- and astrogliosis (Figs. 1 and 2). Modest
effects on TNFa and IL-18 expression by LPS and MSC-EV treat-
ment were detected in serum and brain (Supplemental Fig. S1C
and D). However, IL-18 mRNA and protein expression were mark-
edly increased in the brain whereas circulating IL-1b levels were
not affected (Fig. 3). MSC-EV treatment apparently did not affect
cytokine expression in the current experimental setting.4.1. LPS-induced hypomyelination is ameliorated by MSC-EV
treatment in the developing brain
One consequence of inflammation-induced brain injury is
hypomyelination of white matter tracts (Brehmer et al., 2012;
Favrais et al., 2011). MBP served as a marker for myelination pro-
cesses and was assessed by western blot and immunohistochem-
istry at P11. As shown in representative images in Fig. 4A, LPS
treatment resulted in a decrease of MBP protein expression which
was restored by co-treatment with MSC-EV (Fig. 4A). Quantifica-
tion of protein lysates by western blot analysis isolated fromwhole
hemispheres confirmed these qualitative observations at P11 and
revealed significantly increased levels of MBP expression in MSC-
EV treated animals (Fig. 4B). Analysis of MBP expression at P11
by two-way ANOVA revealed main effects by LPS (F (1,47) = 7.77,
p < 0.01) and MSC-EVs (F (1,47) = 20.55, p < 0.001) but no interac-
tion effects.4.2. MSC EV treatment improves long-term cognitive deficits after
inflammatory brain injury
To evaluate long-term effects of MSC-EV treatment on cognitive
function and motor activity after inflammation-induced brain
injury we tested adolescent (P30) and adult (P90) rats. General
motor activity and anxiety-related behaviour was assessed by Open
Field and revealed that neither LPS nor MSC-EV treatment altered
activity and anxiety parameters of adolescent and adult rats
(Fig. 5A–C). Barnes Maze revealed that learning behaviour is not
affected by MSC-EVs or LPS treatment as three-way ANOVA only
revealed a main effect for time (F (2,99) = 20.75, p < 0.001). All ani-
mals showed the same improvement over time independent of
treatment (Fig. 6A, B). However, the spatial probe test as an indica-
tor for adaptive memory function performed at the fourth day
(Fig. 6C) demonstrated main effects by LPS (F (1,33) = 8.30,
p < 0.01), shown by an impaired latency to find the trained hole.
Co-treatment with MSC-EVs significantly improved this memory
deficit to control levels in adolescent and in adult animals
(Fig 6C). In adolescent rats the protective effect of MSC-EV treat-
ment observed by Barnes Maze for spatiotemporal memory func-
tion was also proven in the Novel Object Recognition test,
demonstrating a reduced exploratory activity at the novel object
in adolescent rats upon neonatal LPS exposure. This indicator for
non-spatial, non-aversive memory function was significantly
improved to control levels by MSC-EV treatment (Fig. 6D).4.3. MSC-EVs restore long-term microstructural white matter
alterations after perinatal inflammation-induced brain injury
To evaluate whether the observed cognitive deficits correlated
with alterations of white matter structures, DT-MRI was obtained
from post-mortem P125 rat brains. In addition to ventricular
enlargement after LPS injection, which was ameliorated by MSC-
EV treatment (Fig. 7A), fractional anisotropy as a measure of white
matter integrity was significantly decreased in the corpus callosum
after neonatal LPS exposure (Fig. 7B). In LPS exposed animals frac-
tional anisotropy was significantly increased almost to control
levels following MSC-EV treatment (Fig. 7B). The observed LPS-
induced fractional anisotropy decrease was related to an increase
of radial diffusivity (D\), which can be generally attributed to
myelination defects (Song et al., 2002). Of note, MSC-EV co-
treatment significantly reduced radial diffusivity compared to LPS
treatment only (Fig. 7C).
Fig. 1. LPS-induced cellular degeneration is ameliorated by MSC-EVs. Systemic inflammation was induced in P3 rat pups by i.p. injection of 0.25 mg/kg LPS. MSC-EVs were
administered i.p. at 3 h before and 24 h after LPS-injection. Cellular degeneration was assessed at P5 by western blot analysis and immunohistochemistry (A-C). Cellular
degeneration was determined by cCaspase 3 protein expression in white matter-enriched protein lysates including cortex and white matter of the corpus callosum, deep
cortical white matter, and external capsule (A, n = 12–15 per group). Quantification of TUNEL-positive cells derived from immunohistochemistry in cortex and in white
matter structures (B and C, n = 6–8 per group). Data are presented as mean + SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
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Due to the multifactorial origin of preterm brain injury affecting
the developing organism at different perinatal time points, no sin-
gle therapy has proven effective for prevention and/or treatment.
Stem cell based approaches attracted particular interest because
of their ease of isolation, characterization, proposed multipotency
and pleiotropic effects yielding the potential to treat this complex
disease.
The present study investigated the therapeutic and regenerative
potential of MSC-EVs in the developing central nervous system
with special emphasis on white matter injury. In our experimental
rodent model of inflammation-induced preterm brain injury at P3,
systemic i.p. MSC-EV application effectively reduced cellular
degeneration, modulated inflammatory responses and decreased
early LPS-induced micro- and astrogliosis. As a consequence from
a modulation of the acute response, MSC-EVs significantly
improved LPS-induced hypomyelination and long-term cognitive
deficits in rats up to adulthood. MRI analyses at adult age (P125)
confirmed MSC-EV treatment-induced structural effects in LPS
exposed animals as fractional anisotropy in white matter struc-
tures was significantly restored almost to control levels. No side
effects such as weight loss, clinical illness or death were detected
in experimental animals, indicating a good tolerance of MSC-EVs.
Our findings are largely in line with previous studies on the
application of MSC-EVs in adult models of acute cerebral tissue
damage, such as acute stroke and traumatic brain injury demon-
strating positive effects on inflammatory responses, neuroprotec-
tion, angiogenesis, neurogenesis and thereby improved long-term
neurological function (Doeppner et al., 2015; Xin et al., 2013;
Zhang et al., 2015).
With MSC treatment similar effects have been observed in the
developing brain. In rodent models of hypoxic-ischemic injury,
representing birth asphyxia in term born infants (van Velthoven
et al., 2011), and in an ovine model of global intrauterine
hypoxia-ischemia (Jellema et al., 2013) systemic application of
MSCs provided neuroprotection by reduction of cell death, inflam-
mation and repair. The hypothesis that EVs are potentially equiva-
lent to MSCs is strengthened by the fact that in adult disease
models including ischemic stroke and acute kidney failure, EVs
derived from MSC conditioned medium were as effective as treat-
ment with the cells themselves (Bruno et al., 2009; Doeppner et al.,2015). In neonatal rats subjected to hypoxic-ischemic injury, con-
ditioned medium of adipose-derived stem cells containing EVs sig-
nificantly protected against hippocampal and cortical volume loss
and improved functional outcome at the age of eight postnatal
weeks (Wei et al., 2015). Findings of the present study are sup-
ported by recent observations of MSC-EV treatment in an ovine
model of intrauterine hypoxia-ischemia. Systemic application of
MSC-EVs to foetuses one hour and four days after induction of glo-
bal umbilical cord ischemia restored brain function by reduction of
seizure burden and preservation of baroreceptor reflex sensitivity
(Ophelders et al., 2016). However, only a tendency to morpholog-
ical improvement was observed, possibly explained by the differ-
ent experimental models and species used. Alternatively, the
quality of MSC-EVs, their concentration or the application protocol
might not have been optimal in this experimental setting. Thus, it
will be important to study optimized MSC-EV production and
treatment schemes in the various experimental models.
The present study focussed on preterm white matter injury,
since myelination is the key to functional activity of axons, allow-
ing them to connect to neurons and strengthen circuitry through-
out the nervous system (de Hoz and Simons, 2015). Using
fractional anisotropy as a marker for tissue microstructure alter-
ations, clinical studies revealed that cognitive and motor deficits
in preterm born infants can be directly related to morphological
abnormalities in particular in white matter regions (Counsell
et al., 2008). Experimental studies including our own demon-
strated that LPS administered in rodents at P3 resulted in a signif-
icant decrease of fractional anisotropy and in an increased radial
diffusivity at P21 in post-mortem ex vivo analyses (Brehmer
et al., 2012). Our results revealed that this decrease in fractional
anisotropy also persists into full adulthood (P125). Neonatal treat-
ment with MSC-EVs restored fractional anisotropy, possibly con-
tributing to the normalized cognitive capacities of experimental
animals at adolescent and adult age.
Whereas in adult rats peripherally administered LPS has been
shown to cause spatial learning deficits assessed by water maze
(Shaw et al., 2001) we did not observe alterations of learning
behaviour which closely resembles results from our previous
study in another preterm brain injury model of oxygen-induced
brain injury (Serdar et al., 2016). However, a memory deficit has
been described after mild systemic inflammation induced by
IL1b-injection between P1 and P5, but not between P6 and P10,
Fig. 2. MSC-EV treatment reduces micro- and astrogliosis after inflammation-induced perinatal brain injury. Microglia and astrocyte cell density was assessed via
immunohistochemistry and western blot analysis in white matter-enriched protein lysates including cortex and white matter of the corpus callosum, deep cortical white
matter, and external capsule of P5 rats after induction of systemic inflammation (0.25 mg/kg LPS, i.p.) at P3. Two repetitive i.p. injections of MSC-EVs were administered at 3 h
before and 24 h post LPS-injection. Representative images of microglia (Iba-1) and astrocytes (GFAP) in the cingulate white matter are presented for each treatment group
(Scale bar: 100 lm) (A). Density of microglia (B) and astrocytes (C) in the cingulate white matter and the internal capsule was quantified by counting Iba-1 positive cells and
by measuring the GFAP-positive area, respectively (n = 7). Protein expression of Iba-1 (D) and GFAP (E) was analysed via Western blot analysis in white matter-enriched brain
fractions including cortex, corpus callosum, deep cortical white matter, and external capsule (n = 12–15 per group). Data are presented as mean + SEM. *p < 0.05, **p < 0.01,
***p < 0.001.
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immature brain (Favrais et al., 2011). In line with these findings,
we observed impairment of long-term spatio-temporal memory
function and recognition memory deficits in rats injected with
LPS at P3. These deficits became evident in adolescent animals as
demonstrated by an increased latency to find the escape hole inthe Barnes Maze and by a reduced exploration time in the Novel
Object Recognition test. The fact that every animal was subjected
to all behavioural tasks (Open Field, Barnes maze, Novel Object
Recognition) starting at P30 and P90, respectively, might be a
limitation of the current study. Experimental tasks performed at
P30 may have altered behaviour in the re-testing session at P90
Fig. 3. Inflammation induced cytokine response is not altered by MSC-EV treatment. Quantification of systemic and local IL-1b concentrations after exposure to LPS (0.25 mg/
kg i.p.) at P3 and two repetitive i.p. injections of MSC-EVs at 3 h before and 24 h post LPS-injection. Pubs were sacrificed 48 h after LPS administration and IL-1b protein
concentrations were determined in serum (A, n = 5–6). In brain samples cerebral IL1b mRNA expression and protein concentration (B, n = 8–9; C, n = 8–9) were measured.
Data are presented as mean + SEM. *p < 0.05, ***p < 0.001.
Fig. 4. MSC-EV treatment restores inflammation-induced hypomyelination. MBP expression, as a key marker for myelination, was analysed by immunohistochemistry and
western blot analysis at P11. Animals were treated with LPS (0.25 mg/kg, i.p.) at P3. MSC-EVs were administered at 3 h before and 24 h post LPS injection. Representative
images derived from immunohistochemical staining for MBP (confocal large scale images, bregma: 3.48 ± 0.2 mm) revealed group differences in the white matter (Scale bar:
200 lm) (A). Quantification of protein expression analysis of whole hemispheres (cerebellum excluded) by western blot analysis (B, n = 10–15 per group). Data are presented
as mean + SEM *p < 0.05, **p < 0.01, ***p < 0.001.
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which may explain the rather modest effects we observed at P90.
Nevertheless, cognitive impairments at adolescent age were lar-
gely ameliorated by administration of MSC-EVs. Clinical observa-
tions indicate that alterations of white matter microstructure in
preterm infants persist into adulthood and are associated with cog-
nitive dysfunction (Allin et al., 2011). From studies in adult neu-
rodegenerative diseases and traumatic brain injury involving
white matter alterations it is further suggested that abnormal
myelin remodelling and white matter connectivity modify axonal
conduction efficiency and correlate with cognitive dysfunction
(Armstrong et al., 2015; Lin et al., 2015). Therefore, we hypothesize
that long-term protection on cognitive deficits by MSC-EVs may
result from preservation of neonatal LPS-induced disturbed white
matter development.
In line with previous preclinical reports the current study
reveals that LPS administered at P3 causes acute inflammation
involving micro- and reactive astrogliosis associated with cellular
degeneration and long-term microstructural alterations of the
developing white matter (Brehmer et al., 2012; Lodygensky et al.,
2014; Nobuta et al., 2012; Smith et al., 2014). Both, microglia
and astrocytes are frequently affected in various types of brain
injury and are profoundly activated in white matter lesions of
periventricular leukomalacia (Haynes et al., 2003; Lodygensky
et al., 2014; Volpe, 2009). Key effector mechanisms of activated
microglia and astrocytes include the secretion of pro-inflammatory cytokines and the production of free radicals thereby
enhancing excitotoxicity which finally culminates in injury of
white matter components (Volpe, 2009). MSCs have been shown
to inhibit LPS-stimulated microglia proliferation in vitro by modu-
lating the cytokine response (Jose et al., 2014). Intravenous admin-
istration of MSCs reduced the acute inflammatory response in the
aforementioned ovine model of intrauterine hypoxia-ischemia, i.e.
microgliosis was diminished (Jellema et al., 2013). However, when
applying MSC-EVs in the same model no anti-inflammatory capac-
ities were detected suggesting individual differences between
experimental settings (Ophelders et al., 2016).
In contrast, immunomodulating activities of MSC-EVs were
shown in a murine ischemic stroke model where MSC-EV treat-
ment suppressed stroke associated lymphopenia and improved
post-stroke symptoms in the same manner as MSCs, which were
the source of the applied MSC-EVs (Doeppner et al., 2015). Further-
more, in vitro analyses combined with a clinical treatment attempt
in steroid-resistant acute graft-versus-host-disease demonstrated
that MSC-EVs suppress inflammatory responses in humans
(Kordelas et al., 2014). Also the present findings in our model of
inflammatory preterm brain injury revealed that beneficial effects
of MSC-EVs on cellular degeneration and hypomyelination were
directly associated with reduced gliosis. Importantly, statistical
analysis revealed strong interplay between LPS exposure and effect
of MSC-EV treatment indicating that EVs exert their full potential
upon an inflammatory stimulus. Therefore, it may be hypothesised
Fig. 5. Motor activity and anxiety-related behaviour is not altered after systemic
inflammation and MSC-EV treatment. General motor activity measured in the Open
Field maze expressed by mean velocity (cm/s) (A) and total travelled distance (B)
measured at P30 (adolescent) and at P90 (adult) after induction of systemic
inflammation (0.25 mg/kg LPS, i.p.) at P3 and MSC-EV treatment at 3 h before and
24 h after LPS injection. Anxiety-related behaviour is illustrated as percent of time
the animals spent in the centre region of the Open Field arena (C). Data are
presented as mean + SEM; *p < 0.05; **p < 0.01; (n = 8–10 per group).
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micro- and astroglia activity as major cellular sources of pro-
inflammatory cytokines (Kim et al., 2011; Li et al., 2008).
Whether systemically applied EVs directly act in the brain
remains unclear. Besides the systemic mode of action (Doeppner
et al., 2015; Kordelas et al., 2014), EVs have been suggested to cross
the blood brain barrier upon an inflammatory stimulus and deliver
RNA-messages to neurons (Ridder et al., 2014). Since LPS is known
to induce an acute pro-inflammatory response in both the periph-
ery and the brain analysis of pro-inflammatory cytokines in our
experimental setting revealed a marked increase in IL-1b mRNAand protein expression in the brain at 48 h post LPS injection even
though circulating IL-1b levels were not affected. This may be
explained by a differential regulation of LPS-induced cytokine
responses in the periphery and the brain (Erickson and Banks,
2011). Analyses on TNFa and IL-18 expression by LPS and MSC-
EVs in serum and brain revealed only modest effects. However,
time points, chosen to correlate findings with our read-outs on
cerebral apoptosis and gliosis might have been too late and acute
treatment effects on cytokine responses might have resolved
(Bilbo et al., 2005; Claypoole et al., 2017; Kendall et al., 2011). Since
MSC-EV application did not influence expression of the selected
pro-inflammatory cytokines, additional analysis of a broader set
of molecules including anti-inflammatory cytokines is needed to
explore the impact of MSC-EV on LPS-induced neuroinflammatory
responses in detail.
An additional target mechanism of MSC-EVs might be the pro-
motion of regeneration since in vivo data showed a remyelinating
effect after intracerebral application of MSCs in models of neonatal
brain injury (Titomanlio et al., 2011; van Velthoven et al., 2010).
We also observed a restoration of myelin structures after systemic
MSC-EV treatment, suggesting that in addition to prevention of
acute cellular degeneration, myelination was promoted. Keeping
the multiple hit hypothesis in the pathogenesis of preterm brain
injury in mind, potential neuroprotective agents need to be applied
for prevention and also treatment of injury and developmental dis-
turbances (Kaindl et al., 2009). In the present study, the first time
point of injection was chosen to secure the full anti-
inflammatory potential of MSC-EVs directly at the beginning when
the inflammatory cascade is evolving. In line with the current liter-
ature (Zhang et al., 2015), an additional dose was administered
after 24 h. Moreover, with this treatment regime we aim to mimic
the complex clinical situation in preterm infants where exact tim-
ing of the injurious insult often remains elusive. However, it is well
possible that repetitive therapeutic doses as used by Doeppner and
co-workers might even potentiate the regenerative effect
(Doeppner et al., 2015). The present study implicates that systemic
injection of MSC-EVs is a feasible route of administration and effec-
tively reduces the primary inflammatory response mediated by
microglia and has long-term neuroprotective potential against
white matter injury.
Even though detailed molecular mechanisms for the described
protective potential of MSC-EVs remain to be clarified in further
studies, a few key molecules of MSC-EVs have been identified in
adult neurodegenerative diseases. For example, it is hypothesised
that specific microRNAs are required to mediate the MSC-EVs’ neu-
roprotective effect (Xin et al., 2012). In the future, the detailed
characterisation of the MSC-EVs content will be of significant
importance to interpret the molecular basis of protection observed
in the present disease model (Konala et al., 2016; Lener et al., 2015;
Mitsialis and Kourembanas, 2016).
In summary, further pre-clinical characterisation of the thera-
peutic potential of MSC-EVs for neonatal brain injury seems highly
warranted. In addition, translation of MSC-EVs as therapeutic con-
cepts into clinical application as an off-the shelf product requires
regulatory categorization within existing frameworks (Börger
et al., 2016).6. Conclusion
Since transplantation of undifferentiated cells renders potential
risks for treatment of human infants such as proliferation and for-
mation of emboli, MSC-EVs are a promising new therapeutic and
regenerative strategy for the developing brain. The findings of
the present study suggest that it seems worthwhile to investigate
their mechanisms of action in further experimental settings of
Fig. 6. MSC-EVs improve cognitive function after perinatal inflammatory brain injury. Cognitive function and learning behaviour were assessed at P30 (adolescent) and at P90
(adult) after induction of systemic inflammation (0.25 mg/kg LPS, i.p.) at P3. MSC-EVs were administered at 3 h before and 24 h after LPS injection. Learning behaviour was
determined over three training days in adolescent (A) and adult (B) animals using the Barnes Maze test measuring the latency to find the escape hole. Cognitive function was
assessed at the fourth day in the probe trial when all holes of the Barnes Maze were closed (C). Effects on cognitive function were further assessed in the Novel Object
Recognition test measuring exploration times at familiar and novel objects. As a measure of cognitive function the ratio of exploration time at the novel object compared to
familiar objects was calculated (D). Data are presented as mean + SEM; *p < 0.05; **p < 0.01; (n = 8–10 per group).
Fig. 7. Long-term white matter microstructure development is restored by MSC-EV treatment. Using DT-MRI long-term microstructural white matter alterations were
analysed at P125 after neonatal exposure to systemic inflammation (0.25 mg/kg LPS, i.p.) at P3. MSC-EVs were administered at 3 h before and 24 h post LPS injection.
Representative illustrations of T2W (b0) images, mean diffusivity (MD), fractional anisotropy, and direction encoded colour (DEC) maps are shown for each treatment group
(A). Fractional anisotropy (B) and radial diffusivity (C) were quantified in the corpus callosum. Data are presented as mean + SEM; *p < 0.05; n = 6 per group.
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required safety standards to make this promising therapy suitable
for clinical trials in infants.Disclosure
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